Ahmed M.T. Riaz

Partner

Ahmed is an experienced trial and transaction attorney focusing on intellectual property issues across a range of industries including pharmaceuticals, medical devices, media and fashion.

Ahmed M.T. Riaz Portrait

A curious and highly analytical attorney with substantive in-house experience, Ahmed is known for his ability to understand complex technologies and develop effective litigation and product development strategies in view of his clients’ business realities.

Ahmed’s litigation practice includes Hatch-Waxman, biosimilar, and trademark disputes. His matters have involved patents purportedly covering well-known pharmaceutical products and methods for using those products.  He also has represented clients in inter partes review (IPR) proceedings.

His transactional practice focuses on technical contractual arrangements for public and private life sciences companies in various commercial and intellectual property transactions including asset acquisitions, licensing, and the conducting and outsourcing of development, manufacturing and supply, marketing and promotion activities.

Ahmed also regularly works with clients to build brand recognition in the marketplace. Prior to joining ArentFox Schiff, Ahmed was in-house counsel for a publicly traded medical device company. In this role, he helped to develop, protect and capitalize on the strategic development of an international intellectual property portfolio and managed multiple litigations. 

Client Work

  • Dish Network LLC et al v. Asia TV USA LTD et al (Successfully represented YuppTV USA, Inc. in obtaining emergency relief as a third party intervenor in the United States District Court for the Southern District of New York. The temporary restraining order barred Asia TV USA Ltd. from terminating its Distribution Agreement or otherwise ceasing transmission of its television channels to our client.)
  • Fresenius Kabi USA, LLC v. FERA Pharmaceuticals, LLC (Successfully represented Fresenius Kabi USA, LLC in obtaining a rare preliminary injunction in federal district court. The injunction barred our client’s competitor from launching a generic version of its patented formulation of levothyroxine, an injectable thyroid hormone. The District Court for the District of New Jersey granted the injunction on the basis that our client was likely to win its patent lawsuit against its competitor.)
  • Hospira, Inc. v. Fresenius Kabi USA, LLC  (Successfully invalidated Hospira’s patents that not only benefited the client’s generic version of Precedex, but further developed the “inherent obviousness” case law for generic drugs. For this case, Schiff’s IP practice received the Hatch-Waxman Impact Case of the Year award in 2020 by LMG Life Sciences.)

Boards, Memberships & Certifications

  • American Bar Association, Intellectual Property Law Section
  • American Intellectual Property Law Association

Professional Activities

Ahmed represents indigent clients seeking asylum in the United States.

Insights